Wegovy Savings Card: How to Get $25/Month (2026 Guide)

What is the Wegovy savings card?

Wegovy is semaglutide, a GLP-1 receptor agonist that Novo Nordisk markets specifically for chronic weight management. The FDA approved it in June 2021 for adults with obesity, or with overweight plus at least one weight-related condition. The Wegovy savings card, which Novo Nordisk runs as its savings offer, is a copay reduction program for patients who have commercial insurance and a valid Wegovy prescription. It does not replace insurance, and it is not a coupon you clip and hand to the cashier. It is applied at the pharmacy counter when your prescription is dispensed, after your insurance has processed the claim.

The list price for Wegovy runs roughly $1,350 to $1,865 per month depending on the pharmacy. Almost no insured patient pays that. The savings offer bridges the gap between your plan's copay and a much lower out-of-pocket figure, which for eligible patients lands at the $25 minimum. Which path is yours depends on your coverage: the savings card if your plan covers Wegovy, the NovoCare self-pay pharmacy if it does not, and the Medicare bridge program if you are on Part D. For the full price stack across every route, see the Semaglutide Cost Guide. This article focuses on the savings card access flow.

Wegovy savings card vs Ozempic savings card: what is different?

Both drugs contain semaglutide, but they are separate brands with separate savings programs. Wegovy carries the obesity and chronic weight management indication; Ozempic carries the type 2 diabetes indication. The minimum copay is the same $25 per month on both cards, but the path to it is harder for Wegovy patients. Many commercial plans cover diabetes drugs while excluding obesity drugs from the formulary, so a Wegovy claim is more likely to hit a coverage wall or a prior authorization than an Ozempic claim. Using the wrong brand's card for the wrong prescription gets rejected at the counter. If you are weighing the two, the Ozempic vs Wegovy comparison explains how the same molecule splits into two indications and two pricing realities.

Is NovoCare different from the Wegovy savings card?

This is the single biggest point of confusion, so here is the clean split. NovoCare is Novo Nordisk's patient support program, and it also runs a direct self-pay pharmacy. The savings card is a retail copay program that works through your commercial insurance. The NovoCare self-pay pharmacy is a separate cash-pay channel that does not touch insurance, with its own pricing from $149 per month for starter doses. They are not interchangeable: you use one or the other depending on whether your plan covers the drug.

The savings card and the NovoCare self-pay pharmacy are two separate programs with different pricing.

Eligibility: who qualifies for the Wegovy savings offer?

Eligibility is where most people get tripped up, so here are the exact rules. Your access tier depends entirely on your insurance status. The table below maps the three situations, and the sections under it spell out each one.

Which Wegovy access path applies to you, based on your insurance status.

Tier 1: commercially insured with Wegovy coverage (the $25 tier)

This is the tier most people mean when they search for the Wegovy savings card. To qualify:

• You have commercial insurance (employer plan, ACA marketplace plan, or similar private coverage) that covers Wegovy.
• You have a valid Wegovy prescription for weight management, generally a BMI of 30 or higher, or 27 or higher with a weight-related condition.
• You are not enrolled in Medicare, Medicaid, Medicare Advantage, TRICARE, the VA, the DoD, or any state prescription assistance program.
• Monthly copay: as little as $25.
• The card covers up to $100 in savings per month, which is the mechanism that lowers an eligible copay toward that $25 floor.

Tier 2: commercially insured but your plan does not cover Wegovy

Many commercial plans exclude obesity medications from their formulary even while covering diabetes drugs. If that is your plan, your Wegovy claim gets rejected, and the $25 floor is out of reach, because the card only reduces cost on a covered claim. You have two moves. First, ask your prescriber to file a formulary exception or appeal, since some plans approve coverage with documentation. Second, if coverage stays denied, the NovoCare self-pay pharmacy covered next is the regulated cash-pay route from $149 per month. Novo Nordisk lists current terms for uncovered plans on its savings offer page, so confirm your figure there before you fill.

NovoCare self-pay pharmacy: the cash-pay alternative

NovoCare's direct pharmacy is a self-pay channel that does not run through insurance, so it is the route for uninsured patients and for those whose plans deny coverage. Pricing as of mid-2026:

• $149 per month for lower starter doses. The 4 mg starter offer is held at $149 through August 31, 2026, after which it rises to $199 per month.
• Self-pay pens for new patients start at $199 per month for the first two monthly fills (an introductory rate available through December 31, 2026), then $349 per month for standard maintenance pens.

Self-pay through NovoCare cannot be combined with insurance, and a prescription is still required. Because these introductory rates are time-limited and dose-specific, confirm your exact price at novocare.com/pharmacy/wegovy.html before you order. For how this cash-pay floor compares to the closest obesity-drug alternative, see the Wegovy vs Zepbound comparison.

Who cannot use the Wegovy savings card?

Federal anti-kickback law sets these exclusions, not Novo Nordisk. They do not bend:

• Medicare Part D patients. Manufacturer copay assistance is prohibited on government-funded prescriptions.
• Medicaid patients. The same statutory restriction applies.
• TRICARE, VA, DoD, and state assistance program patients. All government-funded coverage is excluded.
• Patients without a valid Wegovy prescription for weight management. The card is indication-specific and brand-specific.

Medicare and Wegovy: your options if the savings card is excluded

The Medicare exclusion hits Wegovy harder than it hits Ozempic, so it gets its own section. The difference is indication, not molecule, and it changes what you pay.

Why Medicare Part D does not cover Wegovy for obesity

The Social Security Act, at Section 1860D-2(e)(2)(A), explicitly excludes drugs used for anorexia, weight loss, or weight gain from Part D coverage. Wegovy's approved indication is chronic weight management, which falls squarely inside that exclusion. Ozempic, prescribed for type 2 diabetes, is covered under Part D because diabetes is not an excluded indication. Same active ingredient, different label, very different Medicare outcome. It also leaves Wegovy obesity patients with fewer Medicare fallbacks than diabetes patients have.

Medicare GLP-1 Bridge Program (about $50/month)

The Medicare GLP-1 Bridge is a federal program, not a Novo Nordisk one. Novo participates in it and sets the Wegovy price under it, but as Novo's own pricing page states, "eligibility criteria will be determined by the Centers for Medicare and Medicaid Services (CMS)." That distinction matters: your eligibility is a CMS determination, so a Novo customer service line cannot grant or deny it, and the program is not limited to Wegovy. Under it, eligible Medicare patients prescribed Wegovy for weight loss pay about $50 per month, starting July 1, 2026. This runs separately from the savings card, which is blocked for all Medicare patients. Confirm current eligibility and rates at the official Wegovy pricing page or wegovybridge.novomedlink.com, since both can change.

Pending legislation on Medicare obesity coverage

Legislation to extend Medicare coverage to anti-obesity medications has been introduced in Congress in recent sessions, but it has not changed the Part D exclusion as of mid-2026. If you are a Medicare beneficiary, keep an eye on the current legislative status.

How to enroll in the Wegovy savings offer step by step

Enrollment is straightforward once you do the steps in order. There are five:

1. Get a valid Wegovy prescription from your provider for weight management (BMI of 30 or higher, or 27 or higher with a qualifying condition).
2. Check whether your commercial insurance covers Wegovy by calling the pharmacy benefits number on the back of your insurance card.
3. Enroll online at the Novo Nordisk savings offer page, or by texting SAVE to 83757 to receive the digital savings offer.
4. Present the digital savings offer at the pharmacy so it can be applied at dispensing.
5. Confirm at the counter that your primary insurance was processed first, before the savings offer is applied on top.

Prior authorization: the barrier that matters before the card

Most commercial plans require a prior authorization for Wegovy, meaning your prescriber has to document your weight-related diagnosis before the plan pays anything. This is the step that trips people up, not the card itself. The savings card cannot lower your copay until the claim is approved, so a stalled or denied prior authorization is usually the real reason a fill comes back expensive. If yours is denied, work with your prescriber to appeal. The card is secondary to getting the claim approved.

Does the savings card expire or need renewing?

Novo Nordisk resets its savings program terms periodically and states that it can modify or cancel the program at any time. A stable published expiry date is not something to count on. Check the current expiry and renewal terms at the official enrollment page when you sign up, and again at the start of each year, rather than assuming last year's terms hold.

Common rejection reasons and what to do about them

The pharmacy counter rarely explains why a card does not work. When the savings offer fails to bring your cost down, it is almost always one of these, and each has a fix.

Prior authorization rejected or never submitted

This is the most common root cause. The card cannot offset a claim the pharmacy cannot process. Ask your prescriber's office to initiate or resubmit the prior authorization with the appropriate diagnosis coding for obesity, and to appeal if it was denied.

Government insurance on file

If any government insurance is recorded at the pharmacy, even as a secondary payer, the savings card is ineligible at the system level. Confirm with the pharmacist which insurance is active on your profile, and make sure your commercial plan is set as primary if you have one.

Obesity indication not covered by your plan

If your plan excludes weight-loss drugs, which is common in employer plans, the savings card cannot reach the $25 floor. Your routes are a formulary appeal, or the NovoCare self-pay pharmacy at $149 for starter doses. Some states may require ACA marketplace plans to cover certain weight-loss drugs, so it is worth checking your specific plan's rules.

Prescription is for compounded semaglutide, not branded Wegovy

The savings card applies only to the branded Wegovy pen, not to compounded semaglutide. If your prescription was written for a compounded version, the card will not apply. Confirm with your prescriber that the script is for branded Wegovy if the savings card is your intended route.

Dr. Alicia Shelly, a board-certified internal and obesity medicine physician, walks through the Wegovy insurance coverage process.

How Wegovy compares to Mounjaro and Zepbound on savings card access

Wegovy is not the only GLP-1 with a manufacturer savings card, and the differences come down to indication and cash-pay structure rather than the headline copay.

• All three cards land commercially insured, covered patients at as little as $25 per month. The $25 figure is the industry-standard floor, not a Wegovy-specific perk.
• Mounjaro's card is tied to the type 2 diabetes indication, so its Medicare math is friendlier: Part D covers Mounjaro for diabetes, while it excludes Wegovy for obesity. The Mounjaro Savings Card Guide walks Lilly's equivalent copay program for tirzepatide.
• Zepbound, tirzepatide for obesity, is the closer comparison, since it shares Wegovy's weight-management use case and the same obesity-coverage challenge.
• On cash-pay, the structures diverge. Zepbound offers LillyDirect self-pay vials in the $299 to $449 per month range across doses. Wegovy's self-pay route is the NovoCare pharmacy at $149 for starter doses, with maintenance pens priced higher.

For the full clinical and cost breakdown, see the Wegovy vs Zepbound comparison.